Viewing Study NCT01457040



Ignite Creation Date: 2024-05-05 @ 11:56 PM
Last Modification Date: 2024-10-26 @ 10:42 AM
Study NCT ID: NCT01457040
Status: COMPLETED
Last Update Posted: 2017-10-12
First Post: 2011-10-11

Brief Title: Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia
Sponsor: Nanfang Hospital Southern Medical University
Organization: Nanfang Hospital Southern Medical University

Study Overview

Official Title: A Prospective Study of Intensified Conditioning Regimen With High-Dose-Etoposide for Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia in China
Status: COMPLETED
Status Verified Date: 2015-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Evolving paradigms in the treatment of adult ALL include the application of intense pediatric regimens to the treatment of adolescents and young adults AYA and the optimization of allogeneic hematopoietic stem cell transplantation allo-HSCT in the cure of patients The Cancer and Leukemia Group B CALGB and the Childrens Cancer Group CCG first asked whether AYA between the ages of 16 and 20 fared differently whether they were treated on pediatric protocols The results of this study demonstrated that although the complete remission rates were identical for the AYAs treated on the CALGB and CCG trials the AYAs had a 63 event-free survival EFS and 67 OS at 7 years on the CCG trials compared with 34 and 46 respectively on the CALGB trials

High relapse and transplantation-related-mortality still remains great challenge for HSCT of adult ALL which both range between 25 and 30 Recently risk-adapted indication and optimization of conditioning regimen are highlighted which aiming to reduce TRM and relapse rate respectivelyCity of Hope National Medical Center studied the substitution of etoposide VP-16 for CY in the treatment of ALL patients receiving HCT The result suggested that etoposide and TBI are associated with a decreased relapse rate following transplantation for ALL compared with those receiving CY and TBI Japanese and Germany reports pronounced the advantage of VP-16 in intensified regimen for adult ALL On the same time the investigators previous researches have confirmed the effect and safety of FA-intensified conditioning regimen on relapse and refractary leukemia

Based on mentioned above the investigators speculate that VP-16-intensified conditioning regimen could improve the outcome for adult ALL The potential mechanism will be attributed to reduce MRD and promote GVL effect via providing enough time-window for immuno-reconstitution by high-dose preparative regimen
Detailed Description: In the first decade of the new millennium multiple studies have begun to change our thinking about the treatment of adults with acute lymphoblastic leukemia ALL In pediatric patients cure rates in the range of 80 to 90 are now attainable While adult patients with ALL now have a 90 complete remission CR with modern chemotherapy most patients will relapse and leukemia-free survival with 3 to 7 years of follow-up in large series is only in the range of 30 to 40 The poor outcome of chemotherapy in adults with ALL as compared to children relates to multiple factors including poor tolerance of intensive courses of chemotherapy and a higher incidence of poor prognostic subtypes of ALL such as Philadelphia chromosome-positive ALL and a lower incidence of favorable subtypes such as the t 12 21

Evolving paradigms in the treatment of adult ALL include the application of intense pediatric regimens to the treatment of adolescents and young adults AYA and the optimization of allogeneic hematopoietic stem cell transplantation allo-HSCT in the cure of patients Adult regimens are typically less intense than pediatric regimens The Cancer and Leukemia Group B CALGB and the Childrens Cancer Group CCG first asked whether AYA between the ages of 16 and 20 fared differently whether they were treated on pediatric protocols The results of this study demonstrated that although the complete remission rates were identical for the AYAs treated on the CALGB and CCG trials the AYAs had a 63 event-free survival EFS and 67 OS at 7 years on the CCG trials compared with 34 and 46 respectively on the CALGB trials These results have prompted new studies where pediatric ALL regimens have been adapted to the treatment of younger adults With short follow-up GRAALL-2003 reports suggest EFS and OS outcomes in the range of 60 This improved outcome was more pronounced in the standard-risk patients with a donor who had an OS at 5 years of 69 On the same time our previous researches have confirmed the effect and safety of FA-intensified conditioning regimen on relapse and refractary leukemia

Based on mentioned above we speculate that VP-16-intensified conditioning regimen could improve the outcome for adult ALL The potential mechanism will be attributed to reduce MRD and promote GVL effect via providing enough time-window for immuno-reconstitution by high-dose preparative regimen

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None